Störungen/Besonderheiten der Geschlechtsentwicklung

Kernaussagen

Bei den Störungen der Geschlechtsentwicklung/Besonderheiten der Geschlechtsentwicklung handelt es sich um seltene oder sehr seltene, komplexe Diagnosen. Obwohl phänomenologisch zunächst die besondere Genitalentwicklung im Vordergrund steht, wirken sich genetische und hormonelle Konstellation vielfältig auf extragenitale Eigenschaften betroffener Individuen aus. Zu den wichtigsten Aspekten zählen die hohe Prävalenz von bis zu 30 % assoziierter Fehlbildungen und die Mechanismen einer differenziellen hormonellen Prägung des Gehirns als Einflussfaktor des psychischen Geschlechts.

Aufgrund der vielfältigen Varianten und Verläufe vor dem Hintergrund eines jeweils hoch individuellen psychosozialen Hintergrunds kommt multidisziplinär, holistisch ausgerichteten Kompetenzzentren für DSD eine führende Rolle in der Koordination diagnostischer, beratender und ggf. therapeutischer Maßnahmen zu.

• Literatur

• 1 Hughes IA, Houk C, Ahmed SF et al. Consensus statement on management of intersex disorders. Arch Dis Child 2006; 91: 554-563
• 2 Thyen U, Lanz K, Holterhus PM et al. Epidemiology and initial management of ambiguous genitalia at birth in Germany. Horm Res 2006; 66: 195-203
• 3 Wiesemann C, Ude-Koeller S, Sinnecker GH et al. Ethical principles and recommendations for the medical management of differences of sex development (DSD)/intersex in children and adolescents. Eur J Pediatr 2010; 169: 671-679
• 4 Sinclair AH, Berta P, Palmer MS et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature 1990; 346: 240-244
• 5 Ono M, Harley VR. Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol 2013; 9: 79-91
• 6 Oppelt P, Dörr H-G Hrsg. Kinder- und Jugendgynäkologie. Stuttgart: Thieme; 2014
• 7 Bao AM, Swaab DF. Sex differences in the brain, behavior, and neuropsychiatric disorders. Neuroscientist 2010; 16: 550-565
• 8 Dewing P, Shi T, Horvath S et al. Sexually dimorphic gene expression in mouse brain precedes gonadal differentiation. Brain Res Mol Brain Res 2003; 118: 82-90
• 9 Berenbaum SA. Effects of early androgens on sex-typed activities and interests in adolescents with congenital adrenal hyperplasia. Horm Behav 1999; 35: 102-110
• 10 Meyer-Bahlburg HF, Dolezal C, Baker SW et al. Prenatal androgenization affects gender-related behavior but not gender identity in 5–12-year-old girls with congenital adrenal hyperplasia. Arch Sex Behav 2004; 33: 97-104
• 11 Jürgensen M, Hiort O, Holterhus PM et al. Gender role behavior in children with XY karyotype and disorders of sex development. Horm Behav 2007; 51: 443-453
• 12 Hines M, Ahmed SF, Hughes IA. Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. Arch Sex Behav 2003; 32: 93-101
• 13 Cools M, Drop SL, Wolffenbuttel KP et al. Germ cell tumors in the intersex gonad: old paths, new directions, moving frontiers. Endocr Rev 2006; 27: 468-484
• 14 Achermann JC, Hughes IA. Disorders of Sex Development. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology. Philadelphia: Saunders Elsevier; 2008: 783-848
• 15 Achermann JC, Ito M, Ito M et al. A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 1999; 22: 125-126
• 16 Köhler B, Lin L, Ferraz-de-Souza B et al. Five novel mutations in steroidogenic factor 1 (SF1, NR5A1) in 46,XY patients with severe underandrogenization but without adrenal insufficiency. Hum Mutat 2008; 29: 59-64
• 17 Holterhus PM, Hiort O. Störung der Pubertätsentwicklung. In: Lehnert H, Hrsg. Rationelle Diagnostik und Therapie in Endokrinologie, Diabetologie und Stoffwechsel. Stuttgart: Thieme; 2015
• 18 Hiort O, Holterhus PM, Werner R et al. Homozygous disruption of P450 side-chain cleavage (CYP11A1) is associated with prematurity, complete 46,XY sex reversal, and severe adrenal failure. J Clin Endocrinol Metab 2005; 90: 538-541
• 19 Welzel M, Wüstemann N, Simic-Schleicher G et al. Carboxyl-terminal mutations in 3beta-hydroxysteroid dehydrogenase type II cause severe salt-wasting congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008; 93: 1418-1425
• 20 Flück CE, Tajima T, Pandey AV et al. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet 2004; 36: 228-230
• 21 Richter-Unruh A, Martens JW, Verhoef-Post M et al. Leydig cell hypoplasia: cases with new mutations, new polymorphisms and cases without mutations in the luteinizing hormone receptor gene. Clin Endocrinol 2002; 56: 103-112
• 22 Twesten W, Holterhus P, Sippell WG et al. Clinical, endocrine, and molecular genetic findings in patients with 17beta-hydroxysteroid dehydrogenase deficiency. Horm Res 2000; 53: 26-31
• 23 Cohen-Kettenis PT. Gender change in 46,XY persons with 5alpha-reductase-2 deficiency and 17beta-hydroxysteroid dehydrogenase-3 deficiency. Arch Sex Behav 2005; 34: 399-410
• 24 Sinnecker GH, Hiort O, Dibbelt L et al. Phenotypic classification of male pseudohermaphroditism due to steroid 5 alpha-reductase 2 deficiency. Am J Med Genet 1996; 63: 223-230
• 25 Hiort O, Holterhus PM. The molecular basis of male sexual differentiation. Eur J Endocrinol 2000; 142: 101-110
• 26 Quigley CA, De Bellis A, Marschke KB et al. Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 1995; 16: 271-321
• 27 Hannema SE, Scott IS, Hodapp J et al. Residual activity of mutant androgen receptors explains wolffian duct development in the complete androgen insensitivity syndrome. J Clin Endocrinol Metab 2004; 89: 5815-5822
• 28 Sinnecker GH, Hiort O, Nitsche EM et al. Functional assessment and clinical classification of androgen sensitivity in patients with mutations of the androgen receptor gene. German Collaborative Intersex Study Group. Eur J Pediatr 1997; 156: 7-14
• 29 Hiort O, Sinnecker GH, Holterhus PM et al. Inherited and de novo androgen receptor gene mutations: investigation of single-case families. J Pediatr 1998; 132: 939-943
• 30 Holterhus PM, Wiebel J, Sinnecker GH et al. Clinical and molecular spectrum of somatic mosaicism in androgen insensitivity syndrome. Pediatr Res 1999; 46: 684-690
• 31 Holterhus PM, Werner R, Hoppe U et al. Molecular features and clinical phenotypes in androgen insensitivity syndrome in the absence and presence of androgen receptor gene mutations. J Mol Med 2005; 83: 1005-1013
• 32 Adachi M, Takayanagi R, Tomura A et al. Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 2000; 343: 856-862
• 33 Appari M, Werner R, Wünsch L et al. Apolipoprotein D (APOD) is a putative biomarker of androgen receptor function in androgen insensitivity syndrome. J Mol Med 2009; 87: 623-632
• 34 Holterhus PM, Köhler B, Korsch E, Richter-Unruh A. im Auftrag der Arbeitsgemeinschaft Pädiatrische Endokrinologie (APE) der Deutschen Gesellschaft für Kinderheilkunde und Jugendmedizin (DGKJ) und der Deutschen Gesellschaft für Endokrinologie (DGE). S1-Leitlinie Störungen der Geschlechtsentwicklung. AWMF, Erstellungsdatum 10/2007, letzte Überarbeitung 10/2010. Im Internet: http://www.awmf.org Stand: 08.03.2014
• 35 Wünsch L, Holterhus PM, Wessel L et al. Patients with disorders of sex development (DSD) at risk of gonadal tumour development: management based on laparoscopic biopsy and molecular diagnosis. BJU Int 2012; 110: E958-E965
• 36 Mendez JP, Schiavon R, Diaz-Cueto L et al. A reliable endocrine test with human menopausal gonadotropins for diagnosis of true hermaphroditism in early infancy. J Clin Endocrinol Metab 1998; 83: 3523-3526
• 37 Kubini K, Zachmann M, Albers N et al. Basal inhibin B and the testosterone response to human chorionic gonadotropin correlate in prepubertal boys. J Clin Endocrinol Metab 2000; 85: 134-138
• 38 Rey RA, Belville C, Nihoul-Fékété C et al. Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 1999; 84: 627-631
• 39 Kulle AE, Riepe FG, Melchior D et al. A novel ultrapressure liquid chromatography tandem mass spectrometry method for the simultaneous determination of androstenedione, testosterone, and dihydrotestosterone in pediatric blood samples: age- and sex-specific reference data. J Clin Endocrinol Metab 2010; 95: 2399-2409
• 40 Kulle AE, Welzel M, Holterhus PM et al. Implementation of a liquid chromatography tandem mass spectrometry assay for eight adrenal C-21 steroids and pediatric reference data. Horm Res Paediatr 2013; 16: 22-31
• 41 Krone N, Reisch N, Idkowiak J et al. Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab 2012; 97: E257-E267
• 42 Gillam LH, Hewitt JK, Warne GL. Ethical principles for the management of infants with disorders of sex development. Horm Res Paediatr 2010; 74: 412-418
• 43 Deutscher Ethikrat. Intersexualität (2013). Im Internet: http://www.ethikrat.org/intersexualitaet Stand: 08.03.2014